'Coinciding with rising awareness about the risks of R.S.V., there are finally tools available to prevent severe infections in both infants and older adults.'
#Infection #immunology #vaccines #MonoclonalAntibody #RSV

https://www.nytimes.com/article/rsv-vaccine.html

#IDMastodon @Nature #monoclonalantibody therapy & vaccination For #COVID19 provide similar protection at equivalent neutralizing antibody titers is consistent. Multiple monoclonal antibody products have been shown to be effective as pre- & post-exposure prophylaxis against pre- #omicron variants in many immune-compromised and elderly individuals where immunogenicity & clinical data show considerably impaired responses to vaccination
https://www.nature.com/articles/s41467-023-40204-1

#IDMastodon @Nature Viruses resistant to anti #SarsCoV2 drugs are a major #publichealth concern. #monoclonalantibody Tx face increasing escape mutants with amino acid substitutions in their spike protein. In contrast, antiviral compounds targeting 🦠 proteins other than the spike continue to be efficacious & remain important countermeasures. However, amino acid substitutions that reduce sensitivity to such compounds have been found in viruses isolated from #COVID19 patients

Less is more for monoclonal antibody affinity?
(Particularly if deletion is not the goal)

"This approach delivered higher immune cell activation, in vivo T cell expansion and antitumour activity in the case of CD40. Moreover, an inert anti-4-1BB monoclonal antibody was transformed into an agonist. Low-affinity variants of the clinically important antagonistic anti-PD-1 monoclonal antibody nivolumab also mediated more potent signalling and affected T cell activation."

#Monoclonal #MonoclonalAntibody #immunology #drugdiscovery #drugdevelopment

https://www.nature.com/articles/s41586-022-05673-2

My latest Clinical Pipeline column for #NatureMedicine is out, a look at Moderna's RNA vaccine for RSV & a survey of what's, well, in the pipeline, for RSV immunotherapies, including vaccines and monoclonals.
#Vaccine #drugdiscovery #drugdevelopment #mRNA #RSV #immunology #MonoclonalAntibody

https://www.nature.com/articles/d41591-023-00017-7

My latest Clinical Pipeline column for #NatureMedicine is out today, a look at Moderna's RNA vaccine for RSV & a survey of what's, well, in the pipeline, for RSV immunotherapies, including vaccines and monoclonals.

#Vaccine #drugdiscovery #drugdevelopment #mRNA #RSV #immunology #MonoclonalAntibody

https://www.nature.com/articles/d41591-023-00017-7

"The strong dependence on T cells in MS animal models (experimental autoimmune encephalomyelitis, EAE) and the absence of antibodies in MS have long driven the assumption of MS being orchestrated by T helper cells (12), making those the most plausible therapeutic targets. But anti-CD20 therapies have been a game changer in the MS field."

#Immunology #MultipleSclerosis #MonoclonalAntibody #Autoimmunity

https://www.pnas.org/doi/10.1073/pnas.2221544120

You'll never guess what happened next...

"The key patent on the best-selling anti-inflammatory medication, used to treat conditions like arthritis, was expiring at the end of the year. Regulators had blessed a rival version of the drug, and more copycats were close behind. The onset of competition seemed likely to push down the medication’s $50,000-a-year list price."

#TNF #RheumatoidArthritis #lupus #PublicHealth #Humira #MonoclonalAntibody

https://www.nytimes.com/2023/01/28/business/humira-abbvie-monopoly.html

My latest clinical pipeline column for @NatureMedicine is out today.
It's a look at the recent approval of mosunetuzumab, #Genentech's bispecific anti CD20/CD3 monoclonal antibody
for relapsed or refractory follicular #lymphoma.

#FollicularLymphoma #Hematology #MonoclonalAntibody #DrugDevelopment

https://www.nature.com/articles/d41591-023-00010-0

"Using novel humanized IBC mouse models, we discovered that EGFR-targeted therapy remodels the IBC TME by increasing cytotoxic T cells and reducing immunosuppressive regulatory T cells and M2 macrophages. These changes were due to diminishing immunosuppressive chemokine expression regulated by transcription factor EGR1. We also showed that induction of an immunoactive IBC TME by an anti-EGFR antibody improved the antitumor efficacy of an anti–PD-L1 antibody."

#Immunology #Immunotherapy #EGFR #DrugDevelopment #MonoclonalAntibody

https://www.science.org/doi/10.1126/sciadv.abn7983

"The 18-month investigation, initiated by two congressional committees after the F.D.A. approved the drug, also strongly criticized Biogen, Aduhelm’s manufacturer. Internal documents showed the company set “an unjustifiably high price” of $56,000 a year for Aduhelm because it wanted a history-making “blockbuster” to “establish Aduhelm as one of the top pharmaceutical launches of all time,” even though it knew the high price would burden Medicare and patients, the report found."

#Aduhelm #MonoclonalAntibody #Alzheimer #AlzheimersDisease #Aducanumab

https://www.nytimes.com/2022/12/29/health/alzheimers-drug-aduhelm-biogen.html?action=click&module=Well&pgtype=Homepage&section=Health

Here's the fulcrum of this story, the paper where the Bluestone group and collaborators turn the mouse anti-human CD3 monoclonal into a chimeric, non-Fc activating molecule: Alegre et al, 1994

#MonoclonalAntibody #MolecularBiology #AntibodyEnginering #DrugDiscovery #DrugDevelopment #NatureMedicine #Diabetes #Type1Diabetes #Immunotherapy

https://pubmed.ncbi.nlm.nih.gov/8009586/

My latest clinical pipeline column for Nature Medicine is a look at a drug recently approved by the #FDA to delay the onset of type 1 diabetes.

It's a direct descendant of the very first monoclonal ever approved for clinical use.

#Diabetes #Type1Diabetes #DrugDevelopment #DrugDiscovery #NatureMedicine #Immunology #MonoclonalAntibody

https://www.nature.com/articles/d41591-022-00115-y

#IDMastodon #PedsICU In this #Clinicalreport #monoclonalantibody administration to adolescents and young adults for the prevention/treatment of #COVID19 is generally safe and may be effective to decrease the progression of #COVID19 @MedicineLWW
📌https://journals.lww.com/pidj/Fulltext/2022/12000/Single_Site_Experience_of_the_use_of_Monoclonal.10.aspx?utm_source=email_marketing&utm_medium=email&utm_campaign=health_hlrp_&rid=V_0000000005860596
📌 https://journals.lww.com/pidj/Pages/currenttoc.aspx

'We use data on changes in the in vivo concentration of monoclonal antibodies, and the associated protection from COVID-19, over time to model the dose-response relationship of monoclonal antibodies for prophylaxis. We estimate that 50% protection from COVID-19 is achieved with a monoclonal antibody concentration of 939-fold of the in vitro IC50 (95% CI: 135 - 2073).'

#Preprint #MonoclonalAntibody #Covid#Covid19

https://www.medrxiv.org/content/10.1101/2022.11.22.22282199v1

Not good news on the clinically available monoclonals vs newer covid lineages.

"Our data reveal that emerging omicron sublineages are resistant to most (ie, BA.4.6, BA.2.75.2, and BJ.1) or all (BQ.1.1) clinically used mAbs. As a consequence, in patients at high risk, treatment with mAbs alone might not provide a therapeutic benefit in regions of the globe in which BQ.1.1 is spreading, suggesting that additional treatment options (eg, paxlovid or molnupiravir) should be considered. Furthermore, novel, broadly active mAbs are urgently needed for prophylactic or therapeutic treatment, or both, in patients at high risk."

#COVID #Antibody #MonoclonalAntibody

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00733-2/fulltext

Monoclonal targeting Plasmodium falciparum circumsporozoite protein (PfCSP)

"We conducted a phase 2 trial to assess the safety and efficacy of a single intravenous infusion of CIS43LS against P. falciparum infection in healthy adults in Mali over a 6-month malaria season"

#Plasmodium #Malaria #MonoclonalAntibody #clinicaltrial

https://www.nejm.org/doi/full/10.1056/NEJMoa2206966?query=featured_home

The #Biden regime is eliminating access to #monoclonalantibody treatments in the #UnitedStates #BigPharmaFascism

https://www.naturalnews.com/2022-04-05-14-states-cut-off-from-monoclonal-antibodies.html

Props to Governor Ron DeSantis, One-on-one with America’s Governor: DeSantis expands COVID-19 treatment drug across Florida.
#Florida #monoclonalantibody #news #Regeneron #DeSantis #news #Trump #OneAmericaNews